DE69833649D1 - Ef-1-alpha transkriptionsregulatorische dna aus hamster - Google Patents

Ef-1-alpha transkriptionsregulatorische dna aus hamster

Info

Publication number
DE69833649D1
DE69833649D1 DE69833649T DE69833649T DE69833649D1 DE 69833649 D1 DE69833649 D1 DE 69833649D1 DE 69833649 T DE69833649 T DE 69833649T DE 69833649 T DE69833649 T DE 69833649T DE 69833649 D1 DE69833649 D1 DE 69833649D1
Authority
DE
Germany
Prior art keywords
regulatory dna
hamster
transcriptional regulatory
alpha transcriptional
expression constructs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833649T
Other languages
English (en)
Other versions
DE69833649T2 (de
Inventor
S Allison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of DE69833649D1 publication Critical patent/DE69833649D1/de
Application granted granted Critical
Publication of DE69833649T2 publication Critical patent/DE69833649T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69833649T 1997-05-01 1998-05-01 Ef-1-alpha transkriptionsregulatorische dna aus hamster Expired - Lifetime DE69833649T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US847218 1997-05-01
US08/847,218 US5888809A (en) 1997-05-01 1997-05-01 Hamster EF-1α transcriptional regulatory DNA
PCT/US1998/008906 WO1998049289A1 (en) 1997-05-01 1998-05-01 HAMSTER EF-1α TRANSCRIPTIONAL REGULATORY DNA

Publications (2)

Publication Number Publication Date
DE69833649D1 true DE69833649D1 (de) 2006-04-27
DE69833649T2 DE69833649T2 (de) 2006-12-28

Family

ID=25300098

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833649T Expired - Lifetime DE69833649T2 (de) 1997-05-01 1998-05-01 Ef-1-alpha transkriptionsregulatorische dna aus hamster

Country Status (20)

Country Link
US (1) US5888809A (de)
EP (2) EP1676916A1 (de)
JP (1) JP2000513948A (de)
CN (2) CN100430477C (de)
AT (1) ATE318900T1 (de)
AU (1) AU742561B2 (de)
BR (1) BR9804896B1 (de)
CZ (1) CZ296544B6 (de)
DE (1) DE69833649T2 (de)
DK (1) DK0920498T3 (de)
ES (1) ES2263206T3 (de)
HK (1) HK1022719A1 (de)
HU (1) HU225764B1 (de)
IL (1) IL127897A (de)
NO (1) NO323853B1 (de)
PL (1) PL195604B1 (de)
PT (1) PT920498E (de)
RU (2) RU2249617C2 (de)
SK (1) SK285664B6 (de)
WO (1) WO1998049289A1 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
KR20000046969A (ko) * 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
US20030088061A1 (en) * 2000-10-12 2003-05-08 Staunton Donald E. Materials and methods to modulate ligand binding/enzymatic activity of alpha/beta proteins containing an allosteric regulatory site
AU2002230773A1 (en) * 2000-12-18 2002-07-01 Wyeth Promoters and recombinant expression constructs
DK1808488T3 (da) 2001-07-04 2010-10-18 Chromagenics Bv DNA-sekvenser med anti-repressoraktivitet
EP1513936A2 (de) * 2002-06-14 2005-03-16 Chromagenics B.V. Verwendung von repression hemmende sequenzen in verfahren zur genexpression verbesserung
DK1513937T3 (da) * 2002-06-14 2011-05-16 Chromagenics Bv Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved
CA2510179C (en) * 2002-12-18 2013-04-23 Chromagenics B.V. A method for improving protein production
AU2003290453A1 (en) * 2002-12-20 2004-07-14 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
DK2380985T3 (en) 2003-09-23 2014-03-17 Univ North Carolina Cells expressing the vitamin K epoxide reductase, as well as their use
US8039230B2 (en) * 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
NZ553700A (en) * 2004-11-08 2010-09-30 Chromagenics Bv Selection of host cells expressing protein at high levels using a selectable marker with a non-optimal start codon
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) * 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
CA2581422C (en) * 2004-11-08 2012-05-22 Chromagenics B.V. Selection of host cells expressing protein at high levels
WO2006063292A1 (en) * 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
EP3498289A1 (de) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvalinverbindungen mit phenylalaninseitenkettenmodifikationen am c-terminus
TW200732472A (en) * 2005-10-21 2007-09-01 Hoffmann La Roche Method for the recombinant expression of a polypeptide
ES2461591T3 (es) 2005-10-28 2014-05-20 F. Hoffmann-La Roche Ag Expresión de proteínas en células de roedor
DK1969127T4 (en) * 2005-12-21 2017-10-16 Cnj Holdings Inc Process for the preparation of biologically active vitamin K-dependent proteins by recombinant methods
WO2007081336A1 (en) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Mammalian vectors for high-level expression of recombinant proteins
EP2208792B1 (de) 2006-05-17 2015-05-06 Hoffmann-La Roche AG Polypeptide produzierende Zellen
AU2007269233B2 (en) 2006-06-30 2011-06-09 Cnj Holdings, Inc. Method of producing Factor VIII proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
TW200902544A (en) * 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
EP1975228A1 (de) 2007-03-28 2008-10-01 Fachhochschule Mannheim Polynukleotide für verstärkte Expression eines relevanten Polynukleotids
EP2517714A1 (de) 2007-04-26 2012-10-31 Inspiration Biopharmaceuticals, Inc. Rekombinante Vitamin-K-abhängige Proteine mit hohem Sialsäuregehalt und Verfahren zu ihrer Herstellung
BRPI0813963A2 (pt) * 2007-06-29 2015-01-06 Hoffmann La Roche Mutante de cadeia pesada que leva a uma melhor produção de imunoglobulina
JP5642549B2 (ja) 2007-10-12 2014-12-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 複数の核酸からのタンパク質発現
US7892760B2 (en) 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
UA101497C2 (ru) 2008-04-24 2013-04-10 Селтик Фарма Пег Лтд. Конъюгаты фактора ix с увеличенным временем полужизни
ES2458541T3 (es) 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
KR101800904B1 (ko) 2009-08-06 2017-12-20 씨엠씨 아이코스 바이올로직스, 인크. 재조합 단백질 발현을 개선시키는 방법
EP2478107B1 (de) 2009-09-15 2018-08-29 Medimmune Limited Zellen für transiente expression und ihre verwendung
EP2494040B1 (de) 2009-10-30 2018-08-29 Aptevo BioTherapeutics LLC Verfahren zur herstellung rekombinanter vitamin-k-abhängiger proteine
EP2339009A1 (de) 2009-12-22 2011-06-29 Sandoz Ag Kälteindusierbare Promotorsequenzen
AR081750A1 (es) 2010-03-31 2012-10-17 Boehringer Ingelheim Int Anticuerpos anti-cd40
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
LT2635601T (lt) 2010-11-04 2016-10-10 Boehringer Ingelheim International Gmbh Antikūnai prieš il-23
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
WO2013036130A1 (en) 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
JP5775974B2 (ja) 2011-10-28 2015-09-09 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
ES2930215T3 (es) 2011-12-22 2022-12-07 Hoffmann La Roche Combinaciones de elementos de vector de expresión, procedimientos de generación de células de producción novedosos y su uso para la producción recombinante de polipéptidos
RU2628703C2 (ru) 2011-12-22 2017-08-21 Ф. Хоффманн-Ля Рош Аг Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
SG11201403445YA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Full length antibody display system for eukaryotic cells and its use
ES2749457T3 (es) 2012-01-27 2020-03-20 Prothena Biosciences Ltd Anticuerpos humanizados que reconocen la alfa-sinucleína
CN108324943B (zh) 2012-02-10 2024-03-08 思进股份有限公司 Cd30+癌症的检测和治疗
WO2013123087A1 (en) * 2012-02-14 2013-08-22 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
BR112015011462A2 (pt) 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
LT2971005T (lt) 2013-03-12 2020-10-12 Agc Biologics, Inc. Patobulinta rekombinantinio baltymo ekspresija, naudojant hibridinį chef1 promotorių
ES2766762T3 (es) 2013-03-13 2020-06-15 Prothena Biosciences Ltd Inmunoterapia contra Tau
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
RU2535871C1 (ru) * 2013-07-10 2014-12-20 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") Плазмида для экспрессии в клетке китайского хомячка, клетка китайского хомячка - продуцент белка с Gla-доменом и способ получения белка с Gla-доменом
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
CA2938931A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
TWI718122B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
KR20230110654A (ko) 2015-02-06 2023-07-24 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 viii 유전자 발현 카세트및 그의 용도
WO2016168282A1 (en) 2015-04-14 2016-10-20 Boehringer Ingelheim International Gmbh Methods of treating diseases
CN108025066B (zh) 2015-05-12 2022-04-12 Synt免疫公司 人源化亲和力成熟的抗FcRn抗体
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CA2998716A1 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
TWI733695B (zh) 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
EP3560956A3 (de) 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Verfahren zur behandlung von entzündlichen krankheiten
CN109641045A (zh) 2016-04-25 2019-04-16 Synt免疫公司 人源化亲和力成熟的抗fcrn抗体
UA124148C2 (uk) 2016-05-02 2021-07-28 Протена Біосайенсіс Лімітед Антитіла, що розпізнають тау
CN109415432B (zh) 2016-05-02 2022-07-08 普罗塞纳生物科学有限公司 Tau免疫疗法
KR20230070336A (ko) 2016-05-02 2023-05-22 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP7076711B2 (ja) 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3478715A2 (de) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin-antikörper
EP3478716A2 (de) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin-antikörper
CN109790214B (zh) 2016-09-29 2022-09-06 豪夫迈·罗氏有限公司 用于选择产生多肽的细胞的改进方法
JP2019536756A (ja) 2016-10-14 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ抗体を用いて疾患を処置する方法
WO2018183173A1 (en) 2017-03-27 2018-10-04 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
EP3619233A4 (de) 2017-05-02 2021-03-03 Prothena Biosciences Limited Antikörper zur erkennung von tau
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
CN111801424A (zh) 2018-01-10 2020-10-20 Agc生技制品公司 双向chef1载体
CN112004826A (zh) 2018-02-05 2020-11-27 自由大学基金会 反向激动性抗us28抗体
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
WO2019235923A1 (en) 2018-06-04 2019-12-12 Erasmus University Medical Center Rotterdam Role for low density lipoprotein receptor-related protein 10 in progressive brain diseases
KR20210027436A (ko) 2018-06-29 2021-03-10 베링거 인겔하임 인터내셔날 게엠베하 자가면역 질환을 치료하는데 사용하기 위한 항-cd40 항체
CN110904127A (zh) 2018-09-18 2020-03-24 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
MX2021006134A (es) 2018-11-26 2021-06-23 Forty Seven Inc Anticuerpos humanizados contra c-kit.
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
TW202100141A (zh) 2019-03-08 2021-01-01 德商百靈佳殷格翰國際股份有限公司 抗il-36r抗體調配物
WO2020204714A1 (en) 2019-04-02 2020-10-08 Immunetune B.V. Immune-stimulatory compositions and use thereof
EA202193038A1 (ru) 2019-05-09 2022-03-30 Бёрингер Ингельхайм Интернациональ Гмбх Антитела против sema3a и их применения для лечения заболеваний глаз
TW202115112A (zh) 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
TW202126685A (zh) 2019-09-24 2021-07-16 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
US20210380696A1 (en) 2020-05-26 2021-12-09 Boehringer Ingelheim International Gmbh Anti-pd-1 antibodies
EP4288457A2 (de) 2021-02-05 2023-12-13 Boehringer Ingelheim International GmbH Anti-il1rap-antikörper
WO2023118312A1 (en) 2021-12-22 2023-06-29 Cdr-Life Ag Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
CN114540352A (zh) * 2022-02-16 2022-05-27 艾瑞生命科学技术(常州)有限公司 一种多核苷酸、载体元件及表达载体和宿主细胞及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) * 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
AU645294B2 (en) * 1989-12-22 1994-01-13 Merck Serono Sa Endogenous gene expression modification with regulatory element
US5650294A (en) * 1990-06-25 1997-07-22 Basf Aktiengesellschaft Isolated promoter and terminator of elongation factor 1-α
AU664847B2 (en) * 1991-05-15 1995-12-07 Cell Genesys, Inc. Genomic modifications with homologous DNA targeting
CA2051085C (en) * 1991-09-10 2001-08-21 Shigekazu Nagata Expression plasmids
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery

Also Published As

Publication number Publication date
SK11899A3 (en) 2000-05-16
ES2263206T3 (es) 2006-12-01
NO990025L (no) 1999-03-01
PL331005A1 (en) 1999-06-21
PL195604B1 (pl) 2007-10-31
EP0920498B1 (de) 2006-03-01
AU742561B2 (en) 2002-01-03
CZ28099A3 (cs) 2000-02-16
WO1998049289A1 (en) 1998-11-05
ATE318900T1 (de) 2006-03-15
HU225764B1 (en) 2007-08-28
AU7277098A (en) 1998-11-24
NO990025D0 (no) 1999-01-04
RU2249617C2 (ru) 2005-04-10
CN101570753A (zh) 2009-11-04
DK0920498T3 (da) 2006-07-10
HK1022719A1 (en) 2000-08-18
PT920498E (pt) 2006-08-31
JP2000513948A (ja) 2000-10-24
US5888809A (en) 1999-03-30
HUP0004137A2 (en) 2001-03-28
CN1230991A (zh) 1999-10-06
HUP0004137A3 (en) 2003-08-28
RU2004136574A (ru) 2006-05-27
SK285664B6 (sk) 2007-05-03
CN100430477C (zh) 2008-11-05
CZ296544B6 (cs) 2006-04-12
IL127897A0 (en) 1999-11-30
NO323853B1 (no) 2007-07-16
BR9804896B1 (pt) 2013-11-26
EP1676916A1 (de) 2006-07-05
EP0920498A1 (de) 1999-06-09
BR9804896A (pt) 1999-08-31
DE69833649T2 (de) 2006-12-28
IL127897A (en) 2005-12-18

Similar Documents

Publication Publication Date Title
DE69833649D1 (de) Ef-1-alpha transkriptionsregulatorische dna aus hamster
DK1100880T3 (da) Urat oxidase
BRPI9912663B1 (pt) vacina contra cáncer e polipeptìdeo.
DE69738354D1 (de) Verwendung bestimmter Substanzen für das Verbessern der Wärmestabilität von RNS
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
TR200201588T2 (tr) Yeni bitki tanım yapıları
ATE342911T1 (de) Synthese von nukleosiden und polynukleotiden
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
DE69433978D1 (de) Methode der spezifischen abschaltung von genen durch dna-methylierung
ATE446364T1 (de) Wurzelspezifischer, durch stimulantien induzierbarer promotor und seine verwendung
ATE427959T1 (de) Gereinigtes sr-p70 protein
DE69809930T2 (de) Isolierung und verwendung von nukleinsäuremolekülen, welche für mitglieder der ssx-familie kodieren
ATE335824T1 (de) Isolierte luziferasen sowie deren verwendung
ATE348158T1 (de) Neuartiges collectin
BR0010396A (pt) Composições e métodos para a modificação da expressão de genes
CA2259145A1 (en) Hamster ef-1.alpha. transcriptional regulatory dna
DE69925927D1 (de) Mutmassliches 98 kd protein des aussenmembrans von chlamydia und dafür kodierende dns sowie deren verwendung
BR0016347A (pt) Oligonucleotìdios antisenso
DE60031262D1 (de) Menschliche promotoren des gaba b-rezeptors 1
ATE257862T1 (de) Verwendung von calculus
BR9810643A (pt) Genes e proteìnas de telomerase de vertebrado, eutilização dos mesmos
DK1157105T3 (da) Regulatoriske konstruktioner, der omfatter intron 3 af genet for prostataspecifikt membran-antigen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition